August 16, 2019 09:38 AM EDTUpdated 10:22 AM
Pharma

The top 10 fran­chise drugs in bio­phar­ma his­to­ry will earn a to­tal of $1.4T (tril­lion) by 2024 — what does that tell us?

John Carroll

Editor & Founder

Just in case you were look­ing for more ev­i­dence of just how im­por­tant Am­gen’s patent win on En­brel is for the com­pa­ny and its in­vestors, Eval­u­atePhar­ma has come up with a for­ward-look­ing con­sen­sus es­ti­mate on what the list of top 10 drugs will look like in 2024.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

As cash runs tight, blue­bird plunges af­ter pric­ing sick­le cell gene ther­a­py well above com­peti­tor and fail­ing to win ...

FDA ap­proves two gene ther­a­pies for sick­le cell dis­ease, in­clud­ing first that us­es CRISPR

The End­points 100 sur­vey: Has biotech hit rock bot­tom?

Bris­tol My­ers’ lead deal ne­go­tia­tor to de­part af­ter ink­ing se­ries of multi­bil­lion-dol­lar ac­qui­si­tions

Three big win­ners from Ab­b­Vie's $8.7B Cerev­el deal: A drug­mak­er, a CEO and a SPAC

sponsored

The next phase of de­cen­tral­iza­tion in clin­i­cal tri­als

A service from the Financial Times